Table 2 Treatment regimens and adverse events of CCS patients
No. | Indication for AZA | Dose of AZA at onset (mg/kg per day) | Duration of AZA (months) | Duration of steroids (months) | Combined medications | Clinical Effectiveness | Endoscopic Effectiveness | Adverse events |
|---|---|---|---|---|---|---|---|---|
1 | Augmentation | 0.91 | 98 | 98 | Pred 10 mg qd | Remission | Remission | No |
2 | Steroid-dependent | 1.33 | 24 | 5 | Pred 40 mg qd, tapering | Remission | Response | No |
3 | Steroid-intolerant | 0.81 | 53 | 53 | Pred 5 mg qd, 5-ASA 1 g tid | Remission | Response | Leukopenia |
4 | Augmentation | 1.59 | 60 | NA | NA | Remission | Remission | No |
5 | Steroid-intolerant | 1.52 | 52 | NA | NA | Remission | Response | No |
6 | Augmentation | 1.03 | 17 | 17 | Pred 40 mg qd, tapering | Remission | Response | VZV infection |
7 | Augmentation | 1.70 | 14 | 14 | Pred 20 mg qd, tapering | Response | Recurrence | No |
8 | Augmentation | 1.00 | 1 | 1 | MP 40 mg qd, tapering | NA | NA | PCP infection |
9 | Steroid-dependent | 1.00 | 2 | 2 | Pred 55 mg qd, tapering | NA | NA | Liver dysfunction |
10 | Augmentation | 0.67 | 4 | 4 | Pred 10 mg qd | Remission | Response | No |
11 | Steroid-intolerant | 2.04 | 3 | NA | Tripterygium glycoside | Response | NA | Leukopenia |
12 | Steroid-dependent | 1.72 | 15 | 15 | Pred 10 mg qd | Remission | NA | No |